Work

Op0301 Risk Factors for Anti-infliximab Antibody Formation: Results From the Randomised Controlled Nor-drum a Trial

Year: 2021

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2021-eular.1380

Authors: M.K. Brun, G.L. Goll, K.K. Jørgensen, J. Sexton, J.E. Gehin, Ø. Sandanger, I. Olsen, R.A. Klaasen, D.J. Warren, C. Mørk, T.K. Kvien, J. Jahnsen, N. Bolstad, E.A. Haavardsholm, S.W. Syversen

Institutions: University of Nottingham, University of Oslo, King Abdulaziz University, Diakonhjemmet Hospital, Akershus University Hospital, Arthritis Research UK, Oslo University Hospital

Language: English

Topic: Biosimilars and Bioanalytical Methods

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3164688982

Cites:

Cited by:

Related to: 10